Efalizumab for Moderate to Severe Atopic Dermatitis

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if Raptiva will have beneficial effects in the treatment of patients with moderate to severe atopic dermatitis.

Clinical Trial Description

Atopic dermatitis is a common, highly pruritic, inflammatory skin disease that affects up to 17% of school-aged children. Most cases of childhood atopic dermatitis improve or resolve by adulthood. However, the majority of patients retain some features of atopic dermatitis and some continue to have severe disease that continues to adulthood. Moderate to severe atopic dermatitis cannot be adeuately controlled with topical agents. Consequently many patients are treated with systemic corticosteroids, cyclosporine, azathioprine, methotrexate, and other immunosuppressants that carry the risk of severe atopic dermatitis is greatly needed. The chronic use of current immunosuppressive agents is limited by cumulative end-organ toxicities. We propose inhibition of T cell trafficking to the skin with Raptiva will have beneficial effects in the treatment of patients with moderate to severe atopic dermatitis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00226057
Study type	Interventional
Source	Oregon Health and Science University
Contact
Status	Completed
Phase	Phase 1
Start date	June 2005
Completion date	May 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03563066` - Effect of Benralizumab in Atopic Dermatitis	Phase 2
Terminated	`NCT04086121` - A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032	Phase 2
Recruiting	`NCT04011215` - Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)	N/A
Completed	`NCT04635072` - Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis	Early Phase 1
Completed	`NCT02916888` - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists	N/A
Completed	`NCT01945086` - A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis	Phase 2
Completed	`NCT00541255` - A Long-Term Examination of Asthma From Childhood Through Adolescence
Terminated	`NCT04990440` - A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis	Phase 2
Completed	`NCT02900131` - Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients	Phase 2
Completed	`NCT03568136` - Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis	Phase 2
Recruiting	`NCT01631617` - Effects of Treatments on Atopic Dermatitis	Phase 2
Completed	`NCT03672383` - Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)	N/A
Completed	`NCT03634345` - Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.	Phase 1
Enrolling by invitation	`NCT04761978` - Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
Completed	`NCT03663673` - Effect of Different Skin Creams on TEWL	Phase 1
Recruiting	`NCT05177744` - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed	`NCT03720470` - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Phase 3
Completed	`NCT02637206` - Skin Irritation Study of GSK2894512 Cream	Phase 1
Completed	`NCT05544591` - Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis	Phase 2
Completed	`NCT05094700` - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants	N/A